BioTelemetry (NASDAQ: BEAT) reported Q4 EPS of $0.05, $0.01 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $43.7 million versus the consensus estimate of $43.4 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.